Senior Director, InvestmentsDepartment: Emerging Company Development
Kathy Meserve is a Senior Director of Investments with the Emerging Company Development team at NCBiotech. In this role, Kathy identifies and evaluates early-stage NC-based life science companies for loans, then mentors and supports selected companies with strategic planning, funding pitch preparation, and introductions to investors and strategic partners for follow-on funding, licensing, co-development, or acquisition.
Kathy brings 30 years of experience as a scientist and business executive in the pharmaceutical and biotechnology industry. Prior to joining NCBiotech, as a business development consultant for eight years, Kathy provided European and U.S. pharma, biotech, and medtech company clients with market research, business strategy development, funding advisory services, scouting, due diligence, introductions to corporate partners and licensors, marketing support, and launch planning.
She helped European businesses expand in the U.S. market through corporate partnerships, licensing agreements, and U.S. subsidiary establishment. Kathy has been directly responsible for growing several small life sciences companies by serving in various senior business development roles.
As Director of Science & Technology Evaluation at Calvert Research, Kathy scouted for and evaluated early-stage pharmaceutical assets for investment and acquisition. In project management at GSK, Kathy worked with clinical stage programs keeping teams on track for on-time regulatory submissions and also worked on the commercial launch of Advair®. Kathy began her career working for 10 years as a formulation scientist at Genentech and GSK, gaining experience with various dosage forms.
Kathy earned her B.A. in Biology at the University of California at Santa Cruz with coursework focused on supporting a career in biotechnology. Throughout her career, she has expanded her education with professional courses that include marketing, commercialization, negotiation, project management, and finance.